Last Updated: November 4, 2026

Claims for Patent: 8,986,693

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,986,693

Title:	Use of TNF.alpha. inhibitor for treatment of psoriasis
Abstract:	The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Inventor(s):	Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL), Taylor; Lori K. (Boston, MA), Chartash; Elliot K. (Marietta, GA), Yan; Philip (Vernon Hills, IL), Granneman; George R. (Marco Island, FL)
Assignee:	AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:	14/510,821
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,986,693
Patent Claims:	1. A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis a first dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing, wherein the patient achieves at least Psoriasis Area and Severity Index (PASI) 90 response at week 12 of the treatment. 2. The method of claim 1, wherein adalimumab is comprised in pre-filled syringes for subcutaneous injection. 3. A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said initial dosing, wherein the patient achieves at least PASI 75 response at week 24 of the treatment. 4. The method of claim 3, wherein adalimumab is comprised in pre-filled syringes for subcutaneous injection. 5. A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said initial dosing, wherein when said method is used to treat a population of patients with moderate to severe chronic plaque psoriasis, at least 47% of said patients achieve at least PASI 75 response at week 12 of the treatment. 6. The method of claim 5, wherein adalimumab is comprised in pre-filled syringes for subcutaneous injection. 7. A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said initial dosing, wherein when said method is used to treat a population of patients with moderate to severe chronic plaque psoriasis, at least 53% of said patients achieve at least PASI 75 response at week 24 of the treatment. 8. The method of claim 7, wherein adalimumab is comprised in pre-filled syringes for subcutaneous injection.

Details for Patent 8,986,693

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	⤷ Start Trial	2034-10-09
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	⤷ Start Trial	2034-10-09
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	⤷ Start Trial	2034-10-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,986,693

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Argentina	040603	⤷ Start Trial
Argentina	045710	⤷ Start Trial
Argentina	077474	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.